Australia markets closed

ITOS Jul 2024 11.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
7.500.00 (0.00%)
As of 12:06PM EDT. Market open.
Full screen
Previous close7.50
OpenN/A
Bid4.60
Ask8.00
Strike11.00
Expiry date2024-07-19
Day's range2.33 - 7.50
Contract rangeN/A
VolumeN/A
Open interestN/A
  • Simply Wall St.

    Should Shareholders Reconsider iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package?

    Key Insights iTeos Therapeutics will host its Annual General Meeting on 11th of June Salary of US$578.9k is part of CEO...

  • GlobeNewswire

    iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

    - Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor reduction observed at every belrestotug + dostarlimab dose vs monotherapy- GSK to provide update on GALAXIES program at upcoming investor event in June- RA Capital and Boxer Capital led $120 million registered direct offering at $17.50, representing a premium of approximately 44% to last close- Pro forma ca

  • GlobeNewswire

    iTeos Therapeutics Announces $120 Million Registered Direct Offering

    - Led by existing investors RA Capital Management and Boxer Capital- Purchase price of $17.50 represents a premium of approximately 44% to last close- Further strengthens balance sheet with pro forma cash position of $715 million, extending anticipated runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, May 10, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generatio